阿尼鲁单抗治疗系统性红斑狼疮的真实世界纵向评估:临床结局、安全性及细胞因子与中性粒细胞活性调节
该多中心纵向观察性队列纳入20例活动性SLE成人患者,接受阿尼鲁单抗300 mg每4周静脉输注治疗12个月。结果显示SLEDAI-2K平均分从基线10.9降至3.1(p<0.001),12个月SRI-4应答率64.7%,86%达到LLDAS,50%达到DORIS缓解,且显著减少低密度中性粒细胞及干扰素驱动趋化因子。
要点
- 12个月时86%患者达到LLDAS,50%达到DORIS缓解,糖皮质激素剂量显著减少。
核心结论
- 阿尼鲁单抗可改善活动性SLE患者的临床结局,允许糖皮质激素减量,并降低低密度中性粒细胞及干扰素驱动趋化因子。
研究设计与样本
- 多中心纵向观察性队列,纳入20例活动性SLE成人患者,接受阿尼鲁单抗300 mg每4周静脉输注,随访12个月。
- 排除活动性狼疮肾炎或中枢神经系统受累患者,在基线及第3、6、9、12个月记录临床和实验室指标。
- 采用广义加性模型结合患者水平随机截距分析纵向变化。
主要发现
- 基线平均SLEDAI-2K为10.9±5.0,常见肌肉骨骼、免疫学和皮肤受累。
- 12个月内平均SLEDAI-2K降至3.1(95%CI 1.1至5.1;p<0.001)。
- 意向性治疗分析采用无应答者填补,第12个月SRI-4应答率为64.7%。
- 第12个月86%患者达到LLDAS,50%达到DORIS缓解。
- 医师整体评估从1.6改善至0.2(95%CI 0.0至0.5;p<0.001)。
关键数值与推荐
- 每日泼尼松等效剂量显著减少(p=0.036)。
- 基线接受糖皮质激素的13例患者中11例达到剂量≤5 mg/天,其中3例停用糖皮质激素。
- 12个月药物持续率为65%。
- 阿尼鲁单抗显著降低循环低密度中性粒细胞(p=0.032)、干扰素驱动趋化因子和炎性细胞因子。
临床怎么用
- 对于活动性SLE且无活动性狼疮肾炎或中枢神经系统受累的患者,阿尼鲁单抗可作为改善疾病活动度并助力糖皮质激素减量的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess clinical effectiveness, safety and in vivo effects on cytokines, chemokines and low-density neutrophils (LDNs) in patients with active systemic lupus erythematosus (SLE) treated with anifrolumab over a 12-month real-world follow-up. METHODS: We established a longitudinal, multicentre, observational cohort of adult patients with active SLE receiving anifrolumab 300 mg intravenously every 4 weeks. Patients with active lupus nephritis or central nervous system involvement were excluded. Clinical and laboratory measures were recorded at baseline and at months 3, 6, 9 and 12. Chemokines, cytokines, LDNs and neutrophil extracellular trap degradation products were assessed at the respective time points. Longitudinal changes were analysed using generalised additive models with patient-level random intercepts. RESULTS: Twenty patients were recruited. Baseline mean Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) was 10.9±5.0, with frequent musculoskeletal, immunological and cutaneous involvement. Over 12 months, mean SLEDAI-2K declined to 3.1 (95% CI 1.1 to 5.1; p<0.001). SLE Responder Index-4 response rates were 64.7% at month 12 in intention-to-treat analyses with non-responder imputation. By month 12, 86% of patients reached Lupus Low Disease Activity State and 50% achieved Definition of Remission in SLE remission. Physician Global Assessment improved from 1.6 to 0.2 (95% CI 0.0 to 0.5; p<0.001). Daily prednisolone equivalents were significantly reduced (p=0.036); a dose ≤5 mg/day was achieved in 11/13 patients receiving glucocorticoids at baseline, including three who discontinued glucocorticoids. Drug persistence at 12 months was 65%. Fifty-five adverse events were recorded, of which four were serious. Anifrolumab significantly reduced circulating LDNs (p=0.032), interferon-driven chemokines and inflammatory cytokines. CONCLUSION: This real-world cohort provides clinical and mechanistic evidence that anifrolumab improves clinical outcomes, enables glucocorticoid tapering and reduces LDNs as well as interferon-driven chemokines in patients with active SLE. Safety and drug persistence were consistent with clinical trial data. TRIAL REGISTRATION NUMBER: DRKS00024360.
引用
- Temiz A, Noversa de Sousa R, Schoen J, et al. Real-world longitudinal assessment of anifrolumab in patients with systemic lupus erythematosus: clinical outcomes, safety and modulation of cytokines and neutrophil activity. RMD Open. 2026. PMID: 42373105. doi:10.1136/rmdopen-2026-006806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。